FDA Grants Accelerated Approval for QALSODY (tofersen) for SOD1-ALS, a Major
- FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS | Biogen Biogen
- FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease CNBC
- F.D.A. Approves Drug for Rare Form of A.L.S. The New York Times
- FDA approves new drug for rare form of ALS ABC News
- Drug for rare form of ALS, based in part on WashU research, approved by FDA – Washington University School of Medicine in St. Louis Washington University School of Medicine in St. Louis
- View Full Coverage on Google News
Read More: FDA Grants Accelerated Approval for QALSODY (tofersen) for SOD1-ALS, a Major